Interview with Ronald Christie, VP Interntaional Operations – General…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Address: East Third Ring Road, Chaoyang District, Beijing No. 1 World Financial Center, East Building 18 Zip Code: 100020
Tel: +86 (010) 59615858
Web: http://www.novonordisk.com.cn/documents/home_page/document/index.asp
Novo Nordisk’s products were introduced to the Chinese market as early as the 1960s. In 1994 Novo Nordisk decided to invest in China by setting up Novo Nordisk (Tianjin) Biotechnology Co., Ltd., which was later renamed Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Headquartered in Beijing, Novo Nordisk now employs more than 1,700 employees and has:
• regional offices in Shanghai, Guangzhou, Wuhan, Shenyang, Jinan and Hong Kong,
• production facilities in Tianjin
• a R&D center in Beijing.
Step by step, Novo Nordisk has become the leader in diabetes in China, with a complete organization covering R&D, production, sales and distribution networks.
While providing all major diabetes treatment products and comprehensive diabetes care to people with diabetes in China, Novo Nordisk is also committed to China’s environment and society and has launched social programs such as for example the NovoCare Bus, the NovoCare Club and the “NovoCare Sunshine Program” in Xinjiang, which is an insulin donation program in an earthquake-ravaged area.
R & D, diabetes treatment products, haemostasis management, hormone replacement therapy
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Shawn Xiang, corporate officer and China head at Santen, discusses the eye care specialist’s second-largest market and the challenges of diagnosing and managing eye conditions in China where a lack…
An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue…
A roundup of some of the top stories coming out of China’s pharma industry, including AstraZeneca’s USD 1.92 billion deal with CSPC; Bayer’s new Shanghai incubator; Genentech’s purchase of Regor…
Ronald Tam, CFO of XTALPI, delves into the company’s evolution from its MIT origins to becoming a global leader in AI-driven drug discovery. Tam discusses the strategic decision to expand…
The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director…
A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive…
Yoshio Uchida, President of Daiichi Sankyo China, outlines the company’s strategic focus on Antibody-Drug Conjugates (ADCs) within China’s oncology market and China’s relevant role in the company’s global R&D operations.…
Olivier Dessajan, CEO of Colisée China and Co-President of the French Healthcare Alliance, discusses Colisée’s long-term investment strategies in China, the challenges of navigating the local regulatory environment, and the…
Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships…
Adept at identifying promising biotechs, Qiming Venture Partners-backed companies saw no less than eight IPOs last year. Managing Partner Nisa Leung provides an update on the firm’s activities in light…
Coming to ALK China from an extensive and varied career, Xian Ji has helped build a new strategy for the allergy specialist’s local affiliate, which has led to quintupled business…
A roundup of top stories from China’s pharma industry, including BeiGene’s new US R&D and manufacturing facility; Merck’s purchase of investigational B-cell depletion therapy from Curon Biopharma, and the Chinese…
See our Cookie Privacy Policy Here
